Immuto Scientific has been awarded a $2.5 million Phase II SBIR grant from the National Institutes of Health (NIH), the company announced recently.

According to a release, the grant will help expand the company’s research and development efforts.

“This SBIR grant will allow us to expand our research and development efforts to push the boundaries of structural mass spectrometry and advance drug discovery against challenging targets,” Immuto Scientific CEO Faraz Choudhury said in a statement.

As previously reported, Immuto Scientific’s Plasma-Induced Modification of Biomolecules (PLIMB) technology helps companies understand how effectively a drug binds to its target to improve the effectiveness of the drug.